Audit: QRS - Topical Ferulic Acid for Skin Rejuvenation

Audit conducted on 03/08/2026 05:04 using AI4L + evidence-mcp / Opus 4.8

Iterations

Summary

Items Count
Total 91
Passed 81
Failed 0
N/A 10
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 All values trace to the ER: protocol (0.5% FA, 15% vit C, 1% vit E, morning, daily), benefits/risks tiers, monitoring markers, and time-to-effect all match ER content.
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 Speculative tiers (“Standalone anti-wrinkle efficacy without vitamin C”, “Unknown long-term or systemic effects”) preserve the ER’s tentative framing.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 No strengthening/softening detected; “modest”, “gradual”, “rarely from ferulic acid alone” retained.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Contraindications/Key Interactions come from the ER’s “Key Interactions & Contraindications”; benefits, risks, monitoring map to their correct ER sections.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 The QRS carries no PMIDs, citations, NCT IDs, expert names, or brand names.
1.6 The QRS does not introduce new attributions. 🟢 No attributions introduced.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Objective, evidence-based tone consistent with the ER.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 At-a-glance and tiers are expert yet accessible.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Presents evidence rather than directives.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 Gates and monitoring present facts, not instructions to the reader.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 No recommending/advising language.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person address anywhere in the sheet.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical instrument names (corneometry, cutometry) are necessary biomarker labels carried verbatim from the ER Monitoring table.
2.8 Information is presented in a concise and very compact manner 🟢 Condensed one-page layout.
2.9 It DOES NOT address the reader directly 🟢 No direct address.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Framing matches a proactive, optimization-oriented audience.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Protocol and monitoring assume a committed user.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 Not general-population framing.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Weighting reflects the proactive audience.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 Uses “rejuvenation”; no “anti-aging” voice.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. 🟢 Formal terminology (erythema, dermatitis, laser) throughout.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); Gate headings (“Contraindications”, “Key Interactions”); Tier labels (“High”, “Medium”, “Low”, “Speculative”); Table column headers in Monitoring (“Marker”, “Target”, “Why”) 🟢 All fixed headings, gate labels, tier labels, and table headers are present and unmodified.
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All expected variable spans (header, at_a_glance, action/time cells, benefits/risks tiers, gates, markers, cadence, qualitative items) are present.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 No unaddressed spans were altered.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No source ER section mapped to the QRS is empty.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Monitoring markers and tier labels reflect the ER’s own labels; protocol/time cells are creator-synthesized per sections 10–11.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Labels for ER-labeled content are preserved; no invented labels where the ER supplies one.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji indicators present.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Content is condensed to fit a single page.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Metadata comment (lines 2–14) is the first element after the doctype.
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 YAML delimited by — on lines 3 and 13; preamble text precedes the opening —.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Enclosed in an HTML comment; not rendered.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Values trimmed; only duration (“00:02”) is quoted, correctly, because it contains a colon.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 er_filename: topical_ferulic_acid_skin_2026-0803-0358_Opus_ER.md
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 qrs_prompt_version: 26.7.02 matches QRS.md version.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 qrs_creation_date: 2026-0803-0456
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 qrs_creator_ai_nickname: Opus
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢 Single word “Opus”.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 qrs_creator_ai_fullname: Opus 4.8
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 “Opus 4.8” — nickname plus version, no qualifier.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 qrs_filename: topical_ferulic_acid_skin_2026-0803-0358_Opus_QRS.html
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Consistent with 5.4; all values clean.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 “Topical Ferulic Acid for Skin Rejuvenation - Quick Reference Sheet”; no entity encoding needed.
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 “Topical Ferulic Acid for Skin Rejuvenation”.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 2026-0803-0456 → 08/03/2026.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 “Opus 4.8”.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 Header contains only the standard subline; no extra content.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Condenses the ER Conclusion faithfully.
7.2 [at_a_glance] is no longer than 60 words 🟢 59 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Stabilizer role, doubled photoprotection, texture/tone/recovery, and “rarely from ferulic acid alone” all trace to the Conclusion.
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 Plain-language terms only (antioxidant, vitamins C and E, sun-related damage).
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trial citations.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No effect sizes or statistics.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Derived from the ER “Populations who should avoid or defer” bullet.
8.2 [stop_items] represent the Contraindications from the ER 🟢 Allergy, active dermatitis/rosacea flares, freshly lasered/peeled/sunburned skin and open lesions.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Each item is an <li>.
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 No trailing explanations or dashes; concise facts.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 The ER bullet carries no parenthetical thresholds/time windows requiring preservation; the conditions themselves convey the gate.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER contraindications use no ranking notation.
8.7 If no [stop_items] are present the section is left empty N/A Contraindications are present.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Derived from the ER prescription-topicals and OTC-actives bullets.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 Retinoids, benzoyl peroxide, and strong exfoliating acids; beneficial/additive interactions (antioxidants, sunscreen) correctly excluded.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Each item is an <li>.
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Concise; consequences/mitigations stripped.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Example-drug lists preserved: “(tretinoin, tazarotene)” and “(glycolic, salicylic)”.
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER interactions use no ranking notation.
9.7 If no [caution_items] are present the section is left empty N/A Key Interactions are present.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 Derived from the ER Therapeutic Protocol.
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Formulation, Timing, Frequency.
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three actionable aspects are present and used.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 0.5% FA with 15% vit C + 1% vit E at low pH; morning on clean dry skin before moisturizer/sunscreen; daily single application.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Photoprotection, Texture & Fine Lines, Pigmentation.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Immediate photoprotection (High benefit) first, then texture (Medium), then pigmentation (Medium).
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three time-to-effect aspects are present and used.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 Immediate; 8–12 weeks; several months — all from the ER Practical Considerations.
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A The ER provides time-to-effect information.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 Tiers map to the ER Expected Benefits High/Medium/Low/Speculative headings.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four tier variables present and populated.
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Concise tier summaries only.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 “(Fine Lines, Texture, Elasticity)” reduced to “reduced photoaging signs”.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four benefit subsections contain items.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 Tiers map to the ER Potential Risks & Side Effects headings.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four tier variables present and populated.
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Concise tier summaries only.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parenthetical detail carried through.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four risk subsections contain items.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Derived from the ER Monitoring Protocol table.
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All five markers listed: erythema index, melanin index, hydration (corneometry), elasticity (cutometry), fine-line/texture score, with matching targets and rationale.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 “Reassess tolerability at 1–2 weeks; evaluate appearance at 4 weeks, 12 weeks, then every 3–6 months” matches the ER.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 Derived from the ER “Qualitative markers to self-monitor”.
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All four qualitative markers listed verbatim.

Issues 03/08/2026 05:04

Pass rate 100.00%. No issues found.